These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 20630651)

  • 1. Growth hormone-releasing hormone antagonist induces apoptosis of human endometrial cancer cells through PKCδ-mediated activation of p53/p21.
    Wu HM; Schally AV; Cheng JC; Zarandi M; Varga J; Leung PC
    Cancer Lett; 2010 Dec; 298(1):16-25. PubMed ID: 20630651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone.
    Zhao L; Yano T; Osuga Y; Nakagawa S; Oishi H; Wada-Hiraike O; Tang X; Yano N; Kugu K; Schally AV; Taketani Y
    Int J Oncol; 2008 Mar; 32(3):593-601. PubMed ID: 18292936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells.
    Hohla F; Buchholz S; Schally AV; Seitz S; Rick FG; Szalontay L; Varga JL; Zarandi M; Halmos G; Vidaurre I; Krishan A; Kurtoglu M; Chandna S; Aigner E; Datz C
    Cell Cycle; 2009 Oct; 8(19):3149-56. PubMed ID: 19755849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Essential role of p21/waf1 in the mediation of the anti-proliferative effects of GHRH antagonist JMR-132.
    Volakaki AA; Lafkas D; Kassi E; Schally AV; Papavassiliou AG; Kiaris H
    J Mol Endocrinol; 2008 Nov; 41(5):389-92. PubMed ID: 18765563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth hormone-releasing hormone antagonist inhibits the invasiveness of human endometrial cancer cells by down-regulating twist and N-cadherin expression.
    Wu HM; Huang HY; Schally AV; Chao A; Chou HH; Leung PC; Wang HS
    Oncotarget; 2017 Jan; 8(3):4410-4421. PubMed ID: 28032599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Axis of GHRH and GHRH Receptor on Cell Viability and Apoptosis of the Placental Choriocarcinoma Cell Line.
    Liu AX; Zhang D; Zhu YM; Gao HJ; Jiang JY; Hu XL; Lv PP; Leung PC; Huang HF
    Curr Mol Med; 2016; 16(3):299-311. PubMed ID: 26917260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
    Seitz S; Rick FG; Schally AV; Treszl A; Hohla F; Szalontay L; Zarandi M; Ortmann O; Engel JB; Buchholz S
    Oncol Rep; 2013 Jul; 30(1):413-8. PubMed ID: 23624870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of GHRH antagonists on human glioblastomas and their mechanism of action.
    Pozsgai E; Schally AV; Zarandi M; Varga JL; Vidaurre I; Bellyei S
    Int J Cancer; 2010 Nov; 127(10):2313-22. PubMed ID: 20162575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.
    Stangelberger A; Schally AV; Rick FG; Varga JL; Baker B; Zarandi M; Halmos G
    Prostate; 2012 Apr; 72(5):555-65. PubMed ID: 21796649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway.
    Guo J; Schally AV; Zarandi M; Varga J; Leung PC
    Reprod Biol Endocrinol; 2010 May; 8():54. PubMed ID: 20509930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer.
    Papadia A; Schally AV; Halmos G; Varga JL; Seitz S; Buchholz S; Rick F; Zarandi M; Bellyei S; Treszl A; Szalontay L; Lucci JA
    Horm Metab Res; 2011 Oct; 43(11):816-20. PubMed ID: 22009378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell lines.
    Pozsgai E; Schally AV; Hocsak E; Zarandi M; Rick F; Bellyei S
    Int J Oncol; 2011 Oct; 39(4):1025-32. PubMed ID: 21701777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonist.
    Seitz S; Hohla F; Schally AV; Moder A; Engel JB; Horn F; Varga J; Zarandi M; Ortmann O; Köster F; Buchholz S
    Oncol Rep; 2008 Nov; 20(5):1289-94. PubMed ID: 18949435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of growth hormone-releasing hormone antagonist on decidual stromal cell growth and apoptosis in vitro†.
    Wu HM; Chen LH; Schally AV; Huang HY; Soong YK; Leung PCK; Wang HS
    Biol Reprod; 2022 Jan; 106(1):145-154. PubMed ID: 34792103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases.
    Rick FG; Schally AV; Szalontay L; Block NL; Szepeshazi K; Nadji M; Zarandi M; Hohla F; Buchholz S; Seitz S
    Proc Natl Acad Sci U S A; 2012 Jan; 109(5):1655-60. PubMed ID: 22307626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer.
    Muñoz-Moreno L; Arenas MI; Carmena MJ; Schally AV; Sánchez-Chapado M; Prieto JC; Bajo AM
    Oncotarget; 2016 Aug; 7(32):52195-52206. PubMed ID: 27448980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of experimental small-cell and non-small-cell lung cancers by novel antagonists of growth hormone-releasing hormone.
    Wang H; Zhang X; Vidaurre I; Cai R; Sha W; Schally AV
    Int J Cancer; 2018 Jun; 142(11):2394-2404. PubMed ID: 29435973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitor, Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway.
    Li LH; Zhang PR; Cai PY; Li ZC
    Biomed Pharmacother; 2016 Aug; 82():161-6. PubMed ID: 27470351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia.
    Rick FG; Schally AV; Block NL; Abi-Chaker A; Krishan A; Szalontay L
    Prostate; 2013 Jun; 73(8):873-83. PubMed ID: 23280565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers.
    Klukovits A; Schally AV; Szalontay L; Vidaurre I; Papadia A; Zarandi M; Varga JL; Block NL; Halmos G
    Cancer; 2012 Feb; 118(3):670-80. PubMed ID: 21751186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.